<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842877</url>
  </required_header>
  <id_info>
    <org_study_id>VALYM</org_study_id>
    <nct_id>NCT04842877</nct_id>
  </id_info>
  <brief_title>Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma</brief_title>
  <official_title>A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical&#xD;
      study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with&#xD;
      relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven&#xD;
      cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with&#xD;
      aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma&#xD;
      (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL&#xD;
      patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis.&#xD;
      At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the&#xD;
      cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator&#xD;
      assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each cycle consists of 28 days. Valemetostat tosylate (DS-3201b) is given continuously at 200&#xD;
      mg once daily (QD). The total duration is expected to be approximately 3 years, assuming an&#xD;
      expected enrollment duration of 2 years and a minimum duration of valemetostat tosylate (DS-&#xD;
      3201b) administration of 12 cycles of 28 days for the last enrolled patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug</time_frame>
    <description>ORR according to Lugano Response Criteria (2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>After 3 cycles of treatment (each cycle of 28 days, id est (ie) 3 months)</time_frame>
    <description>CRR according to Lugano response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>After 6 cycles of treatment (each cycle of 28 days, id est (ie) 6 months)</time_frame>
    <description>CRR according to Lugano response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>After 9 cycles of treatment (each cycle of 28 days, id est (ie) 9 months)</time_frame>
    <description>CRR according to Lugano response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>After 12 cycles of treatment (each cycle of 28 days, id est (ie) 12 months)</time_frame>
    <description>CRR according to Lugano response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>After 12 cycles(each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)</time_frame>
    <description>PFS is defined as the time from inclusion into the study to the first observation of documented clinical disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)</time_frame>
    <description>The DoR is defined as the time from attainment of CR or PR based on Lugano Response Criteria 2014 to the date of first documented disease progression, relapse (local assessment) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study)</time_frame>
    <description>The TTR is defined defined as the time from the first dose date to the date of attainment of CR or PR based on Lugano Response Criteria 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE)</measure>
    <time_frame>After 12 cycles of study treatment (each cycle is 28 days) for the last patient included (estimated 3 years of study)</time_frame>
    <description>The frequency of SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>predose</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>1 hour post-dose at Cycle1 Day 1</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>2 hours post-dose at Cycle1 Day 1</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>4 hours post-dose at Cycle1 Day 1</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>5 hours post-dose at Cycle1 Day 1</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>predose at Cycle1 Day 8</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>predose at Cycle1 Day 15</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</measure>
    <time_frame>predose at Cycle1 Day 22</time_frame>
    <description>quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valemetostat tosylate</intervention_name>
    <description>200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>DS-3201b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 - Participants with confirmed histological diagnosis of B-cell non-Hodgkin's lymphoma of&#xD;
        aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary&#xD;
        mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high&#xD;
        grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, transformed indolent&#xD;
        lymphoma and grade 3b follicular lymphoma), FL (grade 1, 2, 3a), MCL, MZL or other indolent&#xD;
        lymphoma (Waldenström macroglobulinemia), or HL according to the World Health Organization&#xD;
        (WHO) 2016 classification of hematopoietic and lymphoid tissue.&#xD;
&#xD;
        2. Participant who had progressive disease (PD) or did not have a response (CR or PR) in&#xD;
        previous systemic therapy, or relapsed or progressed after previous systemic therapy 3.&#xD;
        Participant who has measurable disease by the Lugano criteria (ie longest diameter of a&#xD;
        nodal site &gt; 1.5cm and/or longest diameter of an extranodal site &gt; 1.0 cm) 4. Participant&#xD;
        who had previous standard therapy with at least: (note: patients having received prior&#xD;
        CAR-T therapy can be enrolled):&#xD;
&#xD;
          1. For aggressive B-cell lymphoma : 1 prior line of therapy (in transformed indolent&#xD;
             lymphoma patient must have received at least one line of treatment containing an&#xD;
             anthracycline-based regimen before of after transformation) containing an anti-CD20&#xD;
             antibody and an anthracycline (unless anthracycline-based therapy is contraindicated)&#xD;
             and if patient is considered unable to benefit from intensification treatment with&#xD;
             autologous stem cell transplant (ASCT) as defined by at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Relapsed following, or refractory to, previous ASCT&#xD;
&#xD;
               -  Ineligible for intensification treatment due to age or significant comorbidity&#xD;
&#xD;
               -  Ineligible for intensification treatment due to failure to mobilize an acceptable&#xD;
                  number of hematopoietic stem cells&#xD;
&#xD;
               -  Refused intensification treatment and/or ASCT&#xD;
&#xD;
          2. For FL, MZL and other indolent non-Hodgkin's lymphoma (NHL): 2 prior lines of systemic&#xD;
             therapy with at least one anti-CD20 monoclonal antibody. Local involved field&#xD;
             radiotherapy for limited stage disease is not considered as a previous line. Subjects&#xD;
             with prior ASCT may be included. Note: for Splenic Marginal Zone Lymphoma (SMZL),&#xD;
             splenectomy is considered as one line; for Extranodal Marginal Zone Lymphoma (ENMZL),&#xD;
             Helicobacter pylori eradication is not considered as a previous line.&#xD;
&#xD;
          3. For MCL: 2 prior lines including at least one immunochemotherapy and one BTK&#xD;
             inhibitor.&#xD;
&#xD;
          4. For HL: 3 prior lines including at least one line with anthracycline-based&#xD;
             chemotherapy (unless anthracycline-based therapy is contraindicated), one line&#xD;
             containing brentuximab-vedotin and one line containing an anti-PD1 or anti-PDL1&#xD;
             antibody and must be considered unable to benefit from intensification treatment with&#xD;
             autologous stem cell transplant (ASCT) as defined by at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Relapsed following, or refractory to, previous ASCT&#xD;
&#xD;
               -  Did not achieve at least a partial response to a standard salvage regimen&#xD;
&#xD;
               -  Ineligible for intensification treatment due to age or significant comorbidity&#xD;
&#xD;
               -  Ineligible for intensification treatment due to failure to mobilize an acceptable&#xD;
                  number of hematopoietic stem cells&#xD;
&#xD;
               -  Refused intensification treatment and/or ASCT 5. Participant with Eastern&#xD;
                  Cooperative Oncology Group (ECOG) performance status of 0 to 2 6. Adequate renal&#xD;
                  function defined as calculated creatinine clearance ≥ 40 mL/min per the Cockcroft&#xD;
                  and Gault formula 7. Adequate bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1000/mm3 (≥ 1 × 109/L) without growth factor&#xD;
                  support (G-CSF) for at least 7 days&#xD;
&#xD;
               -  Platelets ≥ 75,000/mm3 (≥ 75 × 109/L) evaluated after at least 7 days since last&#xD;
                  platelet transfusion&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0 g/dL evaluated after at least 7 days since last transfusion 8.&#xD;
                  Adequate liver function:&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 × the upper limit of normal (ULN) except for unconjugated&#xD;
                  hyperbilirubinemia due to Gilbert's syndrome&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) (in the absence of bone disease), alanine&#xD;
                  aminotransferase (ALT), and aspartate aminotransferase (AST) &lt; 3 × ULN (&lt; 5 × ULN&#xD;
                  if subject has liver involvement due to lymphoma) 9. Adequate tissue (surgical&#xD;
                  excision is recommended) for central pathology review and biological&#xD;
                  characterisation 10. Patient being successfully tested for EZH2 mutation status&#xD;
                  at study specific laboratories (for cohort 1, 2 and 2bis) 11. Subjects with a&#xD;
                  history of hepatitis B or C are eligible on the condition that subjects have&#xD;
                  adequate liver function and are hepatitis B surface antigen negative and have&#xD;
                  undetectable serum hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA,&#xD;
                  respectively.&#xD;
&#xD;
                  12. Females of childbearing potential must agree to use an highly effective birth&#xD;
                  control methods (defined in §13.6.1) during the following time periods related to&#xD;
                  this study: 1) for at least 28 days before starting study drug; 2) while&#xD;
                  participating in the study; 3) dose interruptions; and 4) for at least 3 months&#xD;
                  after discontinuation of study treatment 13. Males with partners of childbearing&#xD;
                  potential must agree to use highly effective birth control methods during the&#xD;
                  study and 3 months after last treatment administration 14. Male and female&#xD;
                  participant ≥18 years of age at the time of informed consent 15. Patient covered&#xD;
                  by any social security system (France) 16. Patient who understands and speaks one&#xD;
                  of the country official language 17. Participant who has provided written consent&#xD;
                  to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant with prior exposure to EZH2 inhibitor&#xD;
&#xD;
          2. Participant with active lymphomatous involvement of the central nervous system (CNS)&#xD;
             at screening&#xD;
&#xD;
          3. Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy),&#xD;
             clinically significant toxicities have not resolved to ≤ Grade 1 per CTCAE version&#xD;
             5.0, or prior treatment-related toxicities are clinically unstable and clinically&#xD;
             significant at time of enrollment.&#xD;
&#xD;
          4. Major surgery within 4 weeks before the first dose of study drug.&#xD;
&#xD;
          5. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled&#xD;
             gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the&#xD;
             bioavailability of the drug&#xD;
&#xD;
          6. Subjects currently taking medications that are known moderate or strong CYP3A inducers&#xD;
&#xD;
               -  If currently used, these medications need to be discontinued at least 14 days&#xD;
                  prior to study drug administration; replacement by alternative medications that&#xD;
                  are not moderate or strong CYP3A inducers can be considered according to medical&#xD;
                  need&#xD;
&#xD;
          7. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID&#xD;
             vaccine)&#xD;
&#xD;
          8. Use of any standard or experimental anti-cancer drug therapy within 4 weeks or a&#xD;
             minimum of 3 half lives of the drug, whatever the shortest prior to first&#xD;
             administration of study drug,&#xD;
&#xD;
          9. History of CAR T-cells therapy within 30 days prior to the first dose of study drug&#xD;
&#xD;
         10. History of autologous or allogeneic hematopoietic cell transplantation (HCT) within 90&#xD;
             days prior to the first dose of study drug&#xD;
&#xD;
         11. Patients taking corticosteroids within 2 weeks prior to first administration of study&#xD;
             drug, unless administered at a cumulated dose equivalent of prednisone to ≤ 10mg /day&#xD;
             (within these 2 weeks).&#xD;
&#xD;
         12. Participant with significant cardiovascular impairment: history of congestive heart&#xD;
             failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial&#xD;
             hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the&#xD;
             first dose of study drug; or cardiac ventricular arrhythmia&#xD;
&#xD;
         13. Subjects with malignancies other than B cell lymphomas except subjects who have been&#xD;
             disease-free for 2 years (subjects with a history of a completely resected&#xD;
             non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).&#xD;
&#xD;
         14. Positive serology of human immunodeficiency virus (HIV)&#xD;
&#xD;
         15. Participant with prolongation of corrected QT interval using Fridericia's formula&#xD;
             (QTcF) to &gt; 470 milliseconds (msec) (obtained on average of 3 ECGs)&#xD;
&#xD;
         16. Participant with venous thrombosis or pulmonary embolism not treated&#xD;
&#xD;
         17. Participant with complications of hepatic cirrhosis, interstitial pneumonia, or&#xD;
             pulmonary fibrosis&#xD;
&#xD;
         18. Participant with active infection requiring systemic therapy&#xD;
&#xD;
         19. Woman who are pregnant (positive serum pregnancy test at screening) or breastfeeding&#xD;
&#xD;
         20. Participant who were deemed as inappropriate to participate in the study by the&#xD;
             investigator or coinvestigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Morschhauser, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Bachy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>+33 (4) 27 01 27 37</phone>
    <email>valym@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.Z. Sint Jan AV</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia SNAUWAERT, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvia SNAUWAERT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz OFFNER, MD</last_name>
      <phone>0032 93 32 21 32</phone>
      <email>fritz.offner@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Fritz OFFNER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Tourelle Peltzer</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëtan VANSTRAELEN, MD</last_name>
      <email>etudes.gvanstraelen@chrverviers.be</email>
    </contact>
    <investigator>
      <last_name>etudes.gvanstraelen@chrverviers.be VANSTRAELEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE</last_name>
      <phone>00 32 81 42 38 64</phone>
      <email>marc.andre@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Marc ANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borhane Slama, MD</last_name>
      <phone>+33 (0)4 32 75 31 38</phone>
      <email>bslama@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Borhane Slama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Gay, MD</last_name>
      <phone>+33 (0)5 59 44 32 03</phone>
      <email>jgay@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Julie Gay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, MD</last_name>
      <phone>+335 56 33 32 67</phone>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Fontanet Bijou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gandhi Damaj, MD</last_name>
      <phone>+33 (0) 2 31 27 26 60</phone>
      <email>damaj-gl@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Gandhi Damaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Metropole Savoie - Site Chambery</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Matteo Pica, MD</last_name>
      <phone>+ 33 (0)4 79 96 50 50</phone>
      <email>gian-matteo.pica@ch-metropole-savoie.fr</email>
    </contact>
    <investigator>
      <last_name>Gian Matteo Pica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Guieze, MD</last_name>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Romain Guieze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>François Lemonnier</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Lemonnier, MD</last_name>
      <phone>+ 33 (0)1 49 81 20 51</phone>
      <email>francois.lemonnier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François Lemonnier, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Casasnovas, PhD</last_name>
      <phone>+333 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Casasnovas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chd de Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Morineau, MD</last_name>
      <phone>+33 (0)2 51 44 61 73</phone>
      <email>nadine.morineau@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine Morineau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katell Le Du, MD</last_name>
      <phone>+33 (0)2 43 47 94 93</phone>
      <email>essaisledu@i-l-c.fr</email>
    </contact>
    <investigator>
      <last_name>Katell Le Du, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Sang - CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Schiano de Colella, MD</last_name>
      <phone>+33(0) 4 91 22 38 68</phone>
      <email>schianojm@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Schiano de Colella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Herbaux, PhD</last_name>
      <email>c-herbaux@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Herbaux, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gh Region Mulhouse Et Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Drenou, MD</last_name>
      <phone>+33 (0)3 89 64 75 21</phone>
      <email>drenoub@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Drenou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Le Gouill, MD</last_name>
      <phone>+332 40 08 32 71</phone>
    </contact>
    <investigator>
      <last_name>Steven Le Gouill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emmanuel Bachy</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bachy, PhD</last_name>
      <phone>+334 78 86 43 01</phone>
      <email>emmanuel.bachy@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Bachy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamy de la Chapelle, PhD</last_name>
      <phone>+332 99 28 98 73</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lamy de la Chapelle, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch de Bretagne Atlantique -</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Bonnet, MD</last_name>
      <phone>+33 (0)297014635</phone>
      <email>antoine.bonnet@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Bonnet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapse</keyword>
  <keyword>valemetostat tosylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

